C
Ciloa
Dedicated to the production of fully native membrane proteins on exosomes
About Ciloa
Ciloa is a preclinical biotechnology company that engineers extracellular vesicles (EVs) to create new therapeutics and preventive treatments. The company has developed a proprietary, integrated platform for the production, purification, and qualification of bioengineered EVs, specifically exosomes. This technology allows for the in-vivo customization of exosomes to carry specific membrane proteins, enabling the pursuit of targets that were previously considered undruggable.
Read full description
The company's primary focus is on developing treatments for metabolic diseases, with a lead candidate based on adiponectin for obesity and type 2 diabetes. Ciloa operates in the biopharmaceutical market, collaborating with other entities to advance its drug development projects. Its business model revolves around leveraging its exosome engineering platform to develop a pipeline of drug candidates, funded in part by government grants, such as the France 2030 innovation fund.
At a glance
- Founded
- 2011
- Headquarters
- Montpellier, France
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
France 2030
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ciloa on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ciloa on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.